Antibodies specific for hyperphosphorylated tau and methods of use thereof
US11111290B2 · kind B2 · utility
4Cited by
47References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 27, 2019 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Sep 27, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.